Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

（1）主要目的：在空腹给药条件下，不同场地原料药制备的AR882胶囊（受试制剂T vs 原制剂R）在健康受试者中的相对生物利用度研究。 （2）次要目的：评价广州瑞安博医药科技有限公司研制的AR882胶囊在健康受试者中的安全性和耐受性； （3）探索性目的：研究健康受试者口服AR882胶囊的药效动力学（PD）特征。

（1）主要目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）药代动力学的影响； （2）次要目的：评价广州瑞安博医药科技有限公司研制的AR882胶囊（规格：25 mg）在中国健康受试者中的安全性和耐受性； （3）探索性目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）的药效动力学的影响。

The goal of this clinical trial is to evaluate the efficacy and safety of AR882 Capsules in patients with primary gout and hyperuricemia. The main questions it aims to answer are:
What is the efficacy of AR882 Capsules in reducing serum uric acid levels in patients with primary gout and hyperuricemia?
Researchers will compare AR882 Capsules with Febuxostat Tablets to see :
Phase II: To explore the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia, aiming to determine the dosing regimen for the Phase III study Phase III: To evaluate the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia.
Participants will:
Be randomly assigned to receive either AR882 Capsules or Febuxostat Tablets. Undergo regular assessments of serum uric acid levels. Report any adverse events or side effects experienced during the study.